With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Predicting adult mortality from oral cancer using a machine learning approach.

2.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

3.

Who Bears the Cost of "Forever Chemical" Cleanup?

4.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

5.

How the metastasis of cancer is driven by cellular plasticity.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot